*Sponsored
Market Crux Just Announced (Nasdaq: CVKD) Is Back On Our Radar For Tomorrow Morning—Friday, December 12, 2025.
Full Coverage On (CVKD) Starts Now
Don't Miss The Next Breakout—Get Real-Time Alerts Sent Directly
To Your Phone. Up To 10X Faster Than Email.
Put (CVKD) On Your Radar Before Tomorrow Morning…
December 11, 2025
Friday Focus | (CVKD) Secures Top Spot on Tomorrow's Watchlist Dear Reader, Every so often, a small company quietly steps into a space dominated by giants — not by chance, but by bringing something fundamentally new to the table. In the race to solve one of medicine's longest-running challenges — preventing dangerous clots without increasing bleeding risk — one emerging player continues to make moves that could reshape the anticoagulation landscape. And in a $40B global market that has seen limited real innovation in decades, that kind of progress is hard to overlook. That company is Cadrenal Therapeutics, Inc. (Nasdaq: CVKD) — and unlike the last time we covered this one, its story now includes expanded clinical assets, operational milestones, and a broader pipeline footprint that just put it on the top of our watchlist for tomorrow morning—Friday, December 12, 2025.
But keep in mind, (CVKD) has less than 2M shares listed in its float according to MarketWatch. When companies have small floats like this, the potential for big moves exists if demand begins to change. And with momentum building around its expanding pipeline, even early shifts in attention can have an outsized impact on a company of this size. That's why recent institutional commentary has become even more meaningful. In fact, coverage from two well-known research firms has added another layer of interest to the (CVKD) story. Two major research firms weighed in around that period with strong coverage: - Noble Capital Markets Senior Analyst Robert LeBoyer recently reaffirmed an Outperform rating with a $45 target, suggesting approximately 350% upside potential from its recent $10 range.
- Zacks Small-Cap Research Senior Analyst David Bautz, PhD set a $30 valuation, which suggests 200% upside potential from its recent range.
Both analysts highlighted (CVKD)'s expanding clinical pipeline and disciplined execution, notably the acquisition of Factor XIa assets from eXIthera that broadened (CVKD)'s scope. And this is where the story gets even more exciting— because since our last update, (CVKD) hasn't slowed down. Since then, the company has made several strategic moves that meaningfully expand its reach across both acute and chronic cardiovascular care. These developments form the backbone of what could be one of the most diversified anticoagulation platforms in the space. Pipeline Expansion: Strategic Moves Since Our Last Update
eXIthera Acquisition (Factor XIa Inhibitors)
On September 15, 2025, (CVKD) added eXIthera's portfolio of Factor XIa inhibitors — including frunexian (Phase 2-ready IV agent) and EP-7327 (oral small molecule) — significantly broadening its pipeline across acute and chronic thrombosis settings. Frunexian has been designed for acute scenarios where device-driven contact activation plays a sizable role (e.g., bypass circuits, catheter thrombosis, LVADs). The inclusion of both IV and oral candidates has given (CVKD) a unique dual-platform footprint beyond traditional anticoagulants.
New Asset: VLX-1005 (Phase 2 — HIT Candidate)
Then today, December 11, 2025, (CVKD) announced the acquisition of VLX-1005, a first-in-class Phase 2 12-LOX inhibitor targeting heparin-induced thrombocytopenia (HIT) — a serious immune-mediated consequence of heparin therapy. The asset carries both FDA Orphan Status and Fast Track designations, strengthening the company's positioning in immune-linked clotting risk. This addition brings (CVKD)'s clinical pipeline to three late-stage programs: - Tecarfarin (vitamin K antagonist)
- Frunexian/EP-7327 (Factor XIa inhibitors)
- VLX-1005 (12-LOX inhibitor for HIT)
Together, these reflect a broader strategic expansion into underserved therapeutic areas within the anticoagulation and thrombosis spectrum. And with a platform now spanning chronic care, acute procedural risk, and immune-mediated thrombosis, the scientific foundation behind (CVKD)'s programs becomes even more compelling. Each mechanism targets a different pressure point within cardiovascular medicine, creating a layered approach few emerging companies can match. To understand why this matters, it helps to look at the science powering these programs forward — starting with one of the most closely watched pathways in modern anticoagulation. The Science Driving Interest
Frunexian — Factor XIa Inhibition
Frunexian represents an emerging class of anticoagulants centered on Factor XIa inhibition, a mechanism that may reduce thrombotic risk while limiting bleeding — a challenge with many current therapies like DOACs that target Factor Xa or thrombin directly. Evidence from Phase 1 studies demonstrated frunexian's high potency, rapid clearance, and a profile suited for acute care environments — traits that distinguish it from broader acting anticoagulants. Pipeline Overview: Precision Across Care Settings
See (CVLD)'s Latest Corporate Presentation Here
Tecarfarin (Phase 3-Ready) — A next-generation oral vitamin K antagonist designed for patients with End-Stage Kidney Disease (ESKD), atrial fibrillation, and mechanical heart valves — groups underserved by existing anticoagulants due to unpredictable metabolism or bleeding risk. Frunexian (Phase 2-Ready) — An IV Factor XIa inhibitor tailored for acute procedural or device-associated applications, such as bypass surgery or LVAD support.
EP-7327 (IND-Ready) — An oral Factor XIa inhibitor for chronic thrombotic conditions, complementing frunexian's acute focus.
VLX-1005 (Phase 2) — A 12-LOX inhibitor intended to address immune platelet-mediated clotting risk in HIT, expanding the company's platform into a distinct mechanism. Tecarfarin: A Persistent Focus for Chronic Cardiovascular Risk
Even as the pipeline diversifies, tecarfarin remains Cadrenal's flagship chronic candidate. Its metabolism outside major hepatic pathways aims for more stable and predictable anticoagulation, and management has been actively advancing its readiness for late-stage development. In Q3 2025 (reported Nov. 10, 2025), (CVKD) highlighted progress on tecarfarin's clinical development, completion of its manufacturing under current good manufacturing practices (cGMP), and ongoing work around LVAD and dialysis trial discussions. Operational & Financial Progress Since October
During the third quarter ended September 30, 2025, (CVKD) reported a net loss of $2.7M, consistent with continued advancement of its clinical development strategy. As of that date, the company held $3.9M in cash and approximately 2.1M shares outstanding, reflecting a focused allocation of resources toward late-stage readiness and pipeline expansion. The company's operational efforts remain centered on advancing tecarfarin, maintaining manufacturing preparedness, and supporting the progression of its growing clinical portfolio. A Closer Look at Cadrenal's Broadening Late-Stage
Pipeline and Market Positioning
Cadrenal Therapeutics, Inc. (Nasdaq: CVKD) is advancing a broad late-stage platform aimed at addressing some of the biggest gaps across the $40B anticoagulation market. The company is centered around three key programs. Tecarfarin is a next-generation vitamin K antagonist designed for patients who need more predictable long-term therapy. Frunexian is an intravenous Factor XIa inhibitor built for use in procedures where medical devices can trigger clotting. And VLX-1005 is a first-in-class candidate for heparin-induced thrombocytopenia (HIT), carrying both FDA and EMA Orphan designations as well as Fast Track status. Together, these programs target areas where current options often fall short, supported by early data showing encouraging safety and precision. Cadrenal also highlights steady progress in manufacturing, regulatory planning, and program readiness, backed by a leadership team with deep experience from major pharmaceutical companies. With roughly 2.1M shares outstanding, meaningful insider ownership, and no debt, the company presents a focused strategy built around high-need cardiovascular and clotting-related conditions. 7 Reasons Why (CVKD) Will Be Topping Our Watchlist Tomorrow Morning—Friday, December 12, 2025… 1. Razor-Thin Float: with fewer than 2M shares available, (CVKD) sits in a setup where even modest shifts in demand can create noticeable momentum. 2. Analyst Coverage: two research firms issued targets of $45 and $30 on (CVKD), which suggests 200% to 350% upside potential from its recent $10 range. 3. Triple-Asset Platform: following recent acquisitions, (CVKD) now advances three late-stage clinical programs spanning chronic, acute, and immune-mediated cardiovascular risk. 4. Pipeline Expansion: the addition of frunexian, EP-7327, and VLX-1005 positions (CVKD) across multiple therapeutic pathways within a $40B anticoagulation market, an area where few emerging companies have comparable breadth. 5. Late-Stage Readiness: with tecarfarin progressing toward a pivotal study in ESKD, (CVKD) enters a phase that could shape outcomes in high-need patient groups. 6. Regulatory Advantages: orphan and fast-track designations tied to VLX-1005 help (CVKD) push forward in a rare, immune-driven condition with limited therapeutic options. 7. Consistent Execution: recent operational updates highlight manufacturing progress, clinical planning, and disciplined advancement across programs as (CVKD) expands its footprint. Put (CVKD) On Your Radar Before Tomorrow Morning…
With fewer than 2M shares currently listed as available to the public, (CVKD)'s small float could lead to the potential for big moves if demand begins to shift. Add to that the recent analyst targets of $45 and $30, which suggests 200% to 350% upside potential— alongside a rapidly expanding three-program clinical platform — and it becomes clear why (CVKD) has landed back on our radar. Between its broadened pipeline, late-stage tecarfarin progress, regulatory advantages surrounding VLX-1005, and consistent execution across manufacturing and clinical planning, (CVKD) now stands in a far more dynamic position than it did just weeks ago. We will have all eyes on (CVKD) tomorrow morning. Take a look at (CVKD) before you call it a night. Also, keep a lookout for my morning update, it could be hitting bright and early. Have a good night. Sincerely,
Gary Silver
Managing Editor,
Market Crux | 
0 التعليقات:
إرسال تعليق